{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:28:37Z","timestamp":1772252917213,"version":"3.50.1"},"reference-count":51,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The aim of this study was to evaluate the usefulness of serum interleukin (IL)-37 and IL-18 as disease activity markers of adult-onset Still\u2019s disease (AOSD) and to compare their related clinical features. Forty-five patients with a set of high and subsequent low disease activity status of AOSD were enrolled. Modified Pouchot (mPouchot) score and serologic disease activity markers including levels of IL-37 and IL-18 were compared between high and low disease activity status. The relationships between disease activity parameters and differences in levels of cytokines according to each disease manifestation were evaluated in high disease activity status. mPouchot score and all disease activity markers including IL-37 and IL-18 significantly declined after treatment. Though both cytokines positively correlated with mPouchot score, the two did not correlate with each other in high disease activity status. IL-18 positively correlated with ferritin, AST, and LDH while IL-37 correlated better with CRP. The expression level of IL-37 was related to leukocytosis while IL-18 was related to pleuritis, pneumonitis, abnormal LFT, and hyperferritinemia. In addition, patients in the IL-18 dominant group presented with higher LDH levels and required a higher mean corticosteroid dose. In conclusion, IL-37 and IL-18 are disease activity markers reflecting different aspects of AOSD that can complement each other.<\/jats:p>","DOI":"10.3390\/jcm10050910","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T06:47:20Z","timestamp":1614322040000},"page":"910","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Different Features of Interleukin-37 and Interleukin-18 as Disease Activity Markers of Adult-Onset Still\u2019s Disease"],"prefix":"10.3390","volume":"10","author":[{"given":"Seoung Wan","family":"Nam","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju 26426, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SuMan","family":"Kang","sequence":"additional","affiliation":[{"name":"Hanyang University Institute for Rheumatology Research, Seoul 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7745-3599","authenticated-orcid":false,"given":"Jun Hyeok","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Wonju College of Medicine, Yonsei University, Wonju 26426, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-4008","authenticated-orcid":false,"given":"Dae Hyun","family":"Yoo","sequence":"additional","affiliation":[{"name":"Hanyang University Institute for Rheumatology Research, Seoul 04763, Korea"},{"name":"Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jbspin.2017.05.011","article-title":"New markers for adult-onset still\u2019s disease","volume":"85","author":"Mitrovic","year":"2018","journal-title":"Jt. Bone Spine"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3109\/03009742.2013.824023","article-title":"Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset still\u2019s disease","volume":"43","author":"Jung","year":"2014","journal-title":"Scand. J. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","article-title":"Adult still\u2019s disease: Manifestations, disease course, and outcome in 62 patients","volume":"70","author":"Pouchot","year":"1991","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3899\/jrheum.100247","article-title":"Clinical manifestations but not cytokine profiles differentiate adult-onset still\u2019s disease and sepsis","volume":"37","author":"Rau","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/1529-0131(200107)44:7<1716::AID-ART298>3.0.CO;2-I","article-title":"Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset still\u2019s disease","volume":"44","author":"Kawaguchi","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","article-title":"Mechanisms, biomarkers and targets for adult-onset still\u2019s disease","volume":"14","author":"Feist","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","article-title":"Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset still\u2019s disease","volume":"44","author":"Kawashima","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.130575","article-title":"Interleukin 18: A biomarker for differential diagnosis between adult-onset still\u2019s disease and sepsis","volume":"41","author":"Priori","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Shimizu, T., Kikuchi-Taura, A., Tsuji, S., Matsushita, M., Ohshima, S., and Saeki, Y. (2018). Up-regulation of cd64 expression on monocytes in patients with active adult-onset still disease: A possible biomarker of disease activity. J. Clin. Rheumatol.","DOI":"10.1097\/RHU.0000000000000931"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imr.12605","article-title":"Suppression of inflammation and acquired immunity by il-37","volume":"281","author":"Cavalli","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhao, P.W., Jiang, W.G., Wang, L., Jiang, Z.Y., Shan, Y.X., and Jiang, Y.F. (2014). Plasma levels of il-37 and correlation with tnf-alpha, il-17a, and disease activity during dmard treatment of rheumatoid arthritis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095346"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1479-5876-12-69","article-title":"Il-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Its correlation with disease activity","volume":"12","author":"Ye","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10875-012-9791-z","article-title":"Glucocorticoid regulates interleukin-37 in systemic lupus erythematosus","volume":"33","author":"Song","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12967-015-0394-3","article-title":"Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity","volume":"13","author":"Chen","year":"2015","journal-title":"J. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12967-018-1655-8","article-title":"Plasma interleukin-37 is increased and inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells in systemic juvenile idiopathic arthritis patients","volume":"16","author":"Feng","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13075-018-1555-6","article-title":"Interleukin-37 is increased in adult-onset still\u2019s disease and associated with disease activity","volume":"20","author":"Chi","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","first-page":"424","article-title":"Preliminary criteria for classification of adult still\u2019s disease","volume":"19","author":"Yamaguchi","year":"1992","journal-title":"J. Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3899\/jrheum.120079","article-title":"Serum s100a8\/a9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset still\u2019s disease","volume":"39","author":"Kim","year":"2012","journal-title":"J. Rheumatol."},{"key":"ref_19","first-page":"167","article-title":"New insights in the immunobiology of il-1 family members","volume":"4","author":"Netea","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/cyto.2000.0799","article-title":"Il-1h, an interleukin 1-related protein that binds il-18 receptor\/il-1rrp","volume":"13","author":"Pan","year":"2001","journal-title":"Cytokine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: Back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3058640","DOI":"10.1155\/2018\/3058640","article-title":"Reviews of interleukin-37: Functions, receptors, and roles in diseases","volume":"2018","author":"Jia","year":"2018","journal-title":"BioMed Res. Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.4049\/jimmunol.1401810","article-title":"Il-37 alleviates rheumatoid arthritis by suppressing il-17 and il-17-triggering cytokine production and limiting th17 cell proliferation","volume":"194","author":"Ye","year":"2015","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1042\/BJ20040217","article-title":"Interleukin-1 homologues il-1f7b and il-18 contain functional mrna instability elements within the coding region responsive to lipopolysaccharide","volume":"381","author":"Bufler","year":"2004","journal-title":"Biochem. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/ni.1944","article-title":"Il-37 is a fundamental inhibitor of innate immunity","volume":"11","author":"Nold","year":"2010","journal-title":"Nat. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1038\/ncomms6340","article-title":"The structural basis for receptor recognition of human interleukin-18","volume":"5","author":"Tsutsumi","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni.3103","article-title":"Il-37 requires the receptors il-18ralpha and il-1r8 (sigirr) to carry out its multifaceted anti-inflammatory program upon innate signal transduction","volume":"16","author":"Lo","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/07853890.2014.971052","article-title":"Adult-onset still\u2019s disease-pathogenesis, clinical manifestations, and new treatment options","volume":"47","author":"Kadavath","year":"2015","journal-title":"Ann. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaut.2018.07.018","article-title":"A comprehensive review on adult onset still\u2019s disease","volume":"93","author":"Giacomelli","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.semarthrit.2010.05.003","article-title":"Tocilizumab in refractory adult-onset still\u2019s disease with aseptic meningitis--efficacy of interleukin-6 blockade and review of the literature","volume":"40","author":"Sabnis","year":"2011","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1073\/pnas.1619011114","article-title":"Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance","volume":"114","author":"Cavalli","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/rheumatology\/kew325","article-title":"Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation","volume":"55","author":"Cavalli","year":"2016","journal-title":"Rheumatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14224","DOI":"10.1074\/jbc.RA118.003698","article-title":"Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue","volume":"293","author":"Ballak","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/annrheumdis-2019-216233","article-title":"Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout","volume":"79","author":"Kluck","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","first-page":"2422","article-title":"Serum cytokine profiles in patients with adult onset still\u2019s disease","volume":"30","author":"Choi","year":"2003","journal-title":"J. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kudela, H., Drynda, S., Lux, A., Horneff, G., and Kekow, J. (2019). Comparative study of interleukin-18 (il-18) serum levels in adult onset still\u2019s disease (aosd) and systemic onset juvenile idiopathic arthritis (sjia) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol., 3.","DOI":"10.1186\/s41927-019-0053-z"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset still\u2019s disease: Comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/rheumatology\/keq397","article-title":"Markedly increased il-18 liver expression in adult-onset still\u2019s disease-related hepatitis","volume":"50","author":"Priori","year":"2011","journal-title":"Rheumatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/gut.2003.018572","article-title":"Severe hepatic injury in interleukin 18 (il-18) transgenic mice: A key role for il-18 in regulating hepatocyte apoptosis in vivo","volume":"53","author":"Finotto","year":"2004","journal-title":"Gut"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2169\/internalmedicine1962.30.247","article-title":"Adult-onset still\u2019s disease: Hepatic involvement and various serum markers relating to the disease activity","volume":"30","author":"Motoo","year":"1991","journal-title":"Jpn. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2174\/1871530320666191230141110","article-title":"The biochemical and clinical perspectives of lactate dehydrogenase: An enzyme of active metabolism","volume":"20","author":"Khan","year":"2020","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1034\/j.1600-0528.2002.017418.x","article-title":"Pathophysiological roles of interleukin-18 in inflammatory liver diseases","volume":"174","author":"Tsutsui","year":"2000","journal-title":"Immunol. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1074-7613(00)80111-9","article-title":"Caspase-1-independent, fas\/fas ligand-mediated il-18 secretion from macrophages causes acute liver injury in mice","volume":"11","author":"Tsutsui","year":"1999","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: A critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_45","first-page":"113","article-title":"C-reactive protein and bacterial infection in cirrhosis","volume":"27","author":"Pieri","year":"2014","journal-title":"Ann. Gastroenterol."},{"key":"ref_46","first-page":"844","article-title":"Still disease and the liver-an underappreciated association","volume":"7","author":"Lim","year":"2011","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Slaats, J., Ten Oever, J., van de Veerdonk, F.L., and Netea, M.G. (2016). Il-1beta\/il-6\/crp and il-18\/ferritin: Distinct inflammatory programs in infections. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005973"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.24706","article-title":"Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease","volume":"55","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2177\/jsci.39.37","article-title":"Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (mbda) score","volume":"39","author":"Hirata","year":"2016","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"ref_50","first-page":"2189","article-title":"Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset still\u2019s disease","volume":"31","author":"Chen","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1186\/cc1820","article-title":"Statistics review 6: Nonparametric methods","volume":"6","author":"Whitley","year":"2002","journal-title":"Crit Care"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/5\/910\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:29:06Z","timestamp":1760160546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/5\/910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["jcm10050910"],"URL":"https:\/\/doi.org\/10.3390\/jcm10050910","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-147805\/v1","asserted-by":"object"}]},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]}}}